AbbVie Inc. 8-K

What Happened

• AbbVie filed a Current Report on Form 8-K on July 6, 2026, reporting that its preliminary results for the quarter ended June 30, 2026 are expected to include acquired in‑process R&D (IPR&D) and milestones expense of $291 million on a pre‑tax basis.
• AbbVie says this expense represents an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non‑GAAP diluted earnings per share for Q2 2026. Results for the quarter are not yet finalized and remain subject to close and review.
• The company updated guidance to include the charge: full‑year 2026 adjusted diluted EPS guidance now is $13.91–$14.11, and second‑quarter 2026 adjusted diluted EPS guidance is $3.57–$3.61 (each range includes the Q2 acquired IPR&D/milestones impact).

Key Details

• $291 million pre-tax acquired IPR&D and milestones expense recorded in Q2 2026.
• $0.17 negative impact to both GAAP and adjusted diluted EPS for Q2 2026.
• Updated adjusted diluted EPS guidance: FY 2026 $13.91–$14.11; Q2 2026 $3.57–$3.61.
• AbbVie does not generally forecast acquired IPR&D/milestone expenses due to timing uncertainty; prior April guidance excluded any such post‑Q1 charges.

Why It Matters

• For investors, the $291M charge directly reduced reported and adjusted EPS by $0.17 for the quarter and was large enough to require guidance updates for both the quarter and full year.
• This is a transaction‑related (acquisition/collaboration) expense that AbbVie treats separately from core operating results; while included in this update, AbbVie typically excludes such items from forward non‑GAAP guidance because their timing is uncertain.
• Results remain preliminary and could change upon final close of the quarter; investors should watch the final Q2 financial statements and management commentary for more detail.